(Q40143308)

English

Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management

scientific article published on 11 December 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 September 2017

Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management (English)

1 reference

Europe PubMed Central

17 September 2017

Michael J Sweeting

object named as

M Sweeting

4

0 references

Richard D. Grieve

object named as

R Grieve

7

0 references

author name string

B J Thomson

1

1 reference

Europe PubMed Central

17 September 2017

G Kwong

2

1 reference

Europe PubMed Central

17 September 2017

S Ratib

3

1 reference

Europe PubMed Central

17 September 2017

S D Ryder

5

1 reference

Europe PubMed Central

17 September 2017

D De Angelis

6

1 reference

Europe PubMed Central

17 September 2017

W L Irving

8

1 reference

Europe PubMed Central

17 September 2017

Trent HCV Study Group

9

1 reference

Europe PubMed Central

17 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

11 December 2007

1 reference

Europe PubMed Central

17 September 2017

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

17 September 2017

15

1 reference

Europe PubMed Central

17 September 2017

4

1 reference

Europe PubMed Central

17 September 2017

271-278

1 reference

Europe PubMed Central

17 September 2017

Viral hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00941.X

21 January 2018

The burden of hepatitis C in England

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00941.X

21 January 2018

Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00941.X

21 January 2018

Is severe liver disease a common outcome for people with chronic hepatitis C?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00941.X

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00941.X

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00941.X

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00941.X

21 January 2018

Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00941.X

21 January 2018

The epidemiology of hepatitis C in a UK health regional population of 5.12 million

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00941.X

21 January 2018

Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00941.X

21 January 2018

Histological grading and staging of chronic hepatitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00941.X

21 January 2018

Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00941.X

21 January 2018

Disappointing results of combination therapy for HCV?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00941.X

21 January 2018

Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multicentre randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00941.X

21 January 2018

The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00941.X

21 January 2018

High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00941.X

21 January 2018

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00941.X

21 January 2018

Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00941.X

21 January 2018

Identifiers

10.1111/J.1365-2893.2007.00941.X

1 reference

Europe PubMed Central

17 September 2017

1 reference

Europe PubMed Central

17 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40143308&oldid=1886783870"